Skip to Content
MilliporeSigma
All Photos(1)

Documents

V0400000

Vincristine sulfate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Vincristine sulfate salt, 22-Oxovincaleukoblastine sulfate salt, Leurocristine sulfate salt, VCR

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C46H56N4O10 · H2SO4
CAS Number:
2068-78-2
Molecular Weight:
923.04
Beilstein/REAXYS Number:
3924631
MDL number:
MFCD00084729
UNSPSC Code:
41116107
PubChem Substance ID:
329828976
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

vincristine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−70°C

SMILES string

OS(O)(=O)=O.CC[C@]1(O)CC2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C=O)C7[C@](O)([C@H](OC(C)=O)[C@]8(CC)C=CCN9CC[C@]67C89)C(=O)OC)C1

InChI

1S/C46H56N4O10.H2O4S/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6;1-5(2,3)4/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3;(H2,1,2,3,4)/t28-,37-,38+,39+,42-,43+,44+,45-,46-;/m0./s1

InChI key

AQTQHPDCURKLKT-PNYVAJAMSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Vincristine sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 2 Oral - Muta. 2 - Repr. 2

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 7

1 of 7

Etoposide European Pharmacopoeia (EP) Reference Standard

E2600000

Etoposide

Vinorelbine ditartrate salt hydrate ≥98% (HPLC), powder

Sigma-Aldrich

V2264

Vinorelbine ditartrate salt hydrate

Methylprednisolone European Pharmacopoeia (EP) Reference Standard

M1750000

Methylprednisolone

Asparaginase from Escherichia coli lyophilized powder, 100-300 units/mg protein (biuret)

Sigma-Aldrich

A3809

Asparaginase from Escherichia coli

Doxorubicin hydrochloride 98.0-102.0% (HPLC)

Sigma-Aldrich

D1515

Doxorubicin hydrochloride

Tacrolimus Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1809

Tacrolimus

Dasatinib

Sigma-Aldrich

CDS023389

Dasatinib

K Mihajluk et al.
Cancer letters, 458, 29-38 (2019-05-28)
High grade gliomas (HGGs) are aggressive primary brain tumours with local invasive growth and poor clinical prognosis. Clinical outcome is compounded by resistance to standard and novel therapeutics. We have evaluated reformulated aspirin (IP1867B) alone and in combination with conventional
K Mihajluk et al.
Cancer letters, 458, 29-38 (2019-05-28)
This article has been retracted at the request of the Editor-in-Chief due to concerns regarding the legitimacy of images and data presented in the paper. Though a corrigendum (Can. Lett. Vol. 469, 2020, pages 524-535) was previously published to address
Hany R Guirguis et al.
Annals of hematology, 93(6), 1007-1014 (2014-01-15)
In the pre-rituximab era, transformation of indolent B-cell lymphoma to diffuse large B-cell lymphoma (DLBCL) was associated with an extremely poor outcome and a median post-transformation survival ranging from 1 to 2 years. We evaluated the impact of rituximab-cyclophosphamide, adriamycin, vincristine
Patrick J Stiff et al.
The New England journal of medicine, 369(18), 1681-1690 (2013-11-01)
The efficacy of autologous stem-cell transplantation during the first remission in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate risk or high risk on the International Prognostic Index remains controversial and is untested in the rituximab era. We treated
Richard Delarue et al.
The Lancet. Oncology, 14(6), 525-533 (2013-04-13)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become the standard of care for elderly patients with diffuse large B-cell lymphoma. We aimed to ascertain if a dose-dense R-CHOP regimen administered every 2 weeks (R-CHOP14) was superior
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service